Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting 2026

– Clinical-stage PTK7 ADC KIVU-107 shows strong preclinical anti-tumor activity, favorable pharmacokinetics and improved tolerability – Next-generation CEACAM5 ADC KIVU-305 demonstrates potent preclinical activity and enhanced stability across colorectal and other solid tumor models SAN MATEO, CA — April 15, 2026 – Kivu Bioscience , a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for difficult-to treat cancers, today announced upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17 — 22, in San Diego. “We are excited to present new data at AACR that highlight both the strength of our ADC platform and the continued advancement of our pipeline,” said Mohit Trikha, Ph.D., Chief Executive Officer, Kivu Bioscience. “KIVU-107 has the potential to be a best-inclass PTK7-targeted ADC, designed to overcome the tolerability challenges seen with earlier programs. Our second program, KIVU-305, expands our reach into CEACAM5, reinforcing our ability to develop differentiated ADCs with improved stability, tolerability and anti-tumor activity.” Poster Presentation Details Title: KIVU-107: a clinical-stage, best-in-class PTK7 antibody-drug conjugate (ADC) with favorable PK and an improved tolerability profile Session: Experimental and Molecular Therapeutics Date/Time: Tuesday, April 21, 2026, 2:00 PM – 5:00 PM PT Location: Section 10 Poster Number: 5649 KIVU-107 is an ADC targeting protein tyrosine kinase 7 (PTK7), a validated oncology target associated with tumor-initiating cells and overexpressed across multiple solid tumors. A Phase 1 clinical trial in patients with advanced solid tumors is ongoing (NCT07229313). Title: Preclinical efficacy and safety of KIVU-305, a novel CEACAM5-targeting antibody- drug conjugate (ADC) for colorectal cancer Session Track: Experimental and Molecular Therapeutics Date/Time: Tuesday, April 21, 2026, 2:00 PM – 5:00 PM PT Location: Section 10 Poster Number: 5648 KIVU-305 is a next-generation ADC targeting CEACAM5, a well-validated antigen highly expressed in colorectal, pancreatic, gastric and lung cancers. While earlier CEACAM5targeted ADCs established clinical feasibility, their impact has been limited by efficacy at tolerable doses, underscoring the need for improved linker-payload design. KIVU-305 is designed to address these challenges, with a Phase 1 clinical trial in patients with advanced solid tumors planned for 2026. About Kivu Bioscience Kivu Bioscience is a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for oncology. The company’s proprietary linkerpayload technologies are designed to improve safety and efficacy by minimizing offtarget toxicity. With multiple ADC programs in development and a team of industry veterans, Kivu is advancing innovative therapies for patients with cancer. Kivu is headquartered in San Mateo, CA. For more information, visit www.kivubioscience.com . Media Contact Kimberly Ha KKH Advisors 917-291-5744 [email protected] Prev Previous Kivu Bioscience Appoints Mohit Trikha, Ph.D., as Chief Executive Officer Next BIO 2026: Kivu Bioscience exited stealth late last year to develop “kinder and gentler” antibody-drug conjugates with a lower antibody to payload ratio to improve precision and tolerability Next 2929 Campus Drive, Suite 420, San Mateo CA 94403 Linkedin Site by BKW © 2026 Kivu Bioscience Manage Consent To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions. Functional Functional Always active The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network. Preferences Preferences The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user. Statistics Statistics The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. Marketing Marketing The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage options Manage services Manage {vendor_count} vendors Read more about these purposes Accept Deny View preferences Save preferences View preferences {title} {title} {title} Manage Consent To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions. Functional Functional Always active The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network. Preferences Preferences The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user. Statistics Statistics The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. Marketing Marketing The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage options Manage services Manage {vendor_count} vendors Read more about these purposes Accept Deny View preferences Save preferences View preferences {title} {title} {title} Manage consent Manage consent

The release as fetched from its publisher. kivubioscience.com ↗